Aroa Biosurgery signs exclusive US co-promotion deal with Mölnlycke for Endoform

Source excerpt

AROA and Mölnlycke Partner to Expand U.S. Access to Endoform™ AROA and Mölnlycke Partner to Expand U.S. Access to Endoform™ News provided by Aroa Biosurgery Oct 20, 2026, 20:00 ET Share this article Share to X Share this article Share to X Exclusive co-promotion agreement combines AROA's regenerative tissue technology with Mölnlycke's wound care expertise and commercial reach AUCKLAND, New Zealand , Oct. 20, 2026 /PRNewswire/ -- Aroa Biosurgery Limited (ASX: ARX), a soft tissue regeneration company, has entered into an exclusive agreement with Mölnlycke Healthcare US to co-promote Endoform™ in U.S. post-acute settings, effective October 16, 2026. The agreement combines Endoform and AROA's proprietary AROA ECM™ technology with Mölnlycke's established wound care expertise and commercial reach. It is intended to bring Endoform to more clinicians and patients and support the product's continued growth. AROA retains ownership of Endoform and AROA ECM technology and will continue to manufacture, distribute and supply the product. The arrangement also allows AROA to focus its resources on growing Myriad™ adoption in surgical settings and pursuing the opportunity for Symphony™ in outpatient wound care. "We welcome the opportunity to partner with Mölnlycke, a well-established advanced wound care business known for excellence," said Brian Ward, AROA Founder and CEO. "Mölnlycke's deep expertise in wound care and broad commercial footprint provide a strong platform to bring

Company press release